Alexion Pharmaceuticals to Present Data on Soliris (Eculizumab) and PNH at the 2007 American Society of Hematology (ASH) Annual Meeting
CHESHIRE, Conn., December 07, 2007 /PRNewswire-FirstCall/ -- Alexion Pharmaceuticals, Inc. today announced that data relating to paroxysmal nocturnal hemoglobinuria (PNH), as well as to Soliris(R) (eculizumab), a treatment for patients with PNH, will be presented at the 2007 American Society of Hematology Meeting, December 8 - 11 in Atlanta.
The following abstracts will be presented in a poster session on red cell regulation and disorders of production on Monday, December 10, 2007. The session will open at 10:30 a.m. and poster presentations will be held from 5:00 to 7:00 p.m. for each abstract. Additional information can be accessed through the links provided below.
-- Poster # 897-III: "High Incidence of Progression to Chronic Renal
Insufficiency in Patients with Paroxysmal Nocturnal Hemoglobinuria
(PNH)" Dr. Peter Hillmen et al.
-- Location: Hall B3 and B4
-- http://www.abstracts2view.com/hem07/view.php?nu=HEM07L1_5416
-- Poster # 891-III: "Sustained Improvements in Transfusion
Requirements, Fatigue and Thrombosis with Eculizumab Treatment in
Paroxysmal Nocturnal Hemoglobinuria" Dr. Gerard Socie et al.
-- Location: Hall B3 and B4
-- http://www.abstracts2view.com/hem07/view.php?nu=HEM07L1_5204
-- Poster # 902-III: "Disease-Related Symptoms Reported across a Broad
Population of Patients with Paroxysmal Nocturnal Hemoglobinuria" Dr.
Gabrielle Meyers et al.
-- Location: Hall B3 and B4
-- http://www.abstracts2view.com/hem07/view.php?nu=HEM07L1_5438.
The following abstract will be presented in an oral session on red cell regulation and disorders of production on Tuesday, December 11, 2007. The abstract and presentation information can be accessed at the link provided below.
-- Publication Number 840: "Significant Disease Burden in Paroxysmal
Nocturnal Hemoglobinuria Patients with Lower Levels of Hemolysis,
Mild Anemia and Minimal Transfusion: Clinical Improvement with
Eculizumab Therapy" Dr. Monica Bessler et al.
-- Location: Rooms B213-B214
-- Tuesday, December 11, 2007 - 8:45 a.m.
-- http://www.abstracts2view.com/hem07/view.php?nu=HEM07L1_5302.
CONTACT: Irving Adler, Sr. Director of Corporate Communications at AlexionPharmaceuticals, Inc., +1-203-272-8210; Media, Mark Marmur of Makovsky &Company, +1-212-508-9670, or Investors, Rhonda Chiger of Rx Communications,+1-917-322-2569, both for Alexion Pharmaceuticals, Inc.
Ticker Symbol: (NASDAQ-NMS:ALXN)
Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights
reserved.
A United Business Media Company
Posted: December 2007
